查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1511791

外分泌胰臟功能不全診斷市場規模、佔有率、趨勢分析報告：依診斷方法、最終用途、地區、細分市場預測，2024-2030年

Exocrine Pancreatic Insufficiency Diagnostics Market Size, Share & Trends Analysis Report By Diagnostic Method (Laboratory, Imaging), By End-use (Hospitals & Clinics, Research Institutes), By Region, And Segment Forecasts, 2024 - 2030
出版日期: | 出版商: Grand View Research | 英文 125 Pages | 商品交期: 2-10個工作天內

價格

外分泌胰臟功能不全診斷市場的成長與趨勢：

Grand View Research, Inc.最新報告顯示，到2030年，全球外分泌胰臟功能不全診斷市場規模預計將達到54.4億美元，2024年至2030年複合年成長率為7.2%。

胰臟外分泌功能不全 (EPI) 診斷對於該疾病的識別和治療至關重要，特別是考慮到該疾病在不同患者群體中的高盛行率及其與多種根本原因的關聯。診斷的主要促進因素之一是慢性胰臟炎患者的盛行率。研究表明，約 60% 至 90% 的慢性胰臟炎患者在診斷後 10 至 12 年內普遍存在 EPI。慢性胰臟炎是EPI的重要原因，其相對較高的盛行率凸顯了早期發現和治療的重要性。

此外，晚期胰臟癌也是與此疾病密切相關的疾病之一。研究表明，66% 至 92% 的晚期胰腺癌患者會出現 EPI。這些患者的 EPI 早期診斷可以更好地管理症狀並提高生活品質。發炎性腸道疾病(IBD) 也與 EPI 相關，研究顯示 14% 至 74% 的 IBD 患者可能會出現 EPI。及時診斷和治療這些患者的外分泌胰臟功能不全，有助於緩解症狀、改善營養狀況。

此外，儘管服用酵素和營養食品，接受減重手術的患者仍有發生 EPI 的風險。這凸顯了持續監測和診斷測試以確定該患者群體中胰臟外分泌功能不全的重要性。此外，愛滋病毒/愛滋病患者中 EPI 的盛行率估計為 26% 至 45%。早期發現這些患者的外分泌胰臟功能不全對於最佳化營養狀況和整體健康結果至關重要。

與外分泌胰臟功能不全相關的多種病理強調需要全面的診斷方法。推動外分泌胰臟功能不全診斷劑需求的因素包括其在不同患者群體中的高盛行率、其與慢性胰臟炎和胰臟癌等慢性疾病的關聯，以及對有效管理和改善患者預後的需求，其中包括早期診斷的重要性。診斷技術的進步將擴大實現早期檢測和個人化管理，從而改善患者護理和治療結果。

ChiRhoClin, Inc.、Certest Biotec、ScheBo Biotech AG、Immundiagnostik AG 和 Laboratory Corporation of America Holdings 等主要市場參與企業處於外分泌胰腺功能不全診斷創新的前沿。這些公司不斷致力於擴大其產品範圍。例如，2021年6月，CERTEST BIOTEC宣布將參加8月4日至8日在加州舉行的第71屆AACC年度學術會議和臨床實驗室展覽會，展示其最新進展。

胰臟外分泌功能不全診斷市場報告亮點

  • 根據診斷方法，實驗室檢測領域在 2023 年以最高的收益佔有率主導整個市場。這是由於實驗室自動化、一次性套件、樣本收集和儲存、分析等方面的廣泛進步。
  • EPI 診斷研發的擴大預計將在預測期內推動市場成長。
  • 新技術和檢測方法的引入以及現有技術的整合代表了診斷學的重要進步。隨著診斷技術進步的推動，人們對胰臟疾病的認知不斷提高，用於 EPI 診斷的美國糞便檢驗市場預計將在未來幾年繼續擴大。
  • 由於多種因素，醫院和診所最終用途細分市場將在 2023 年佔據市場主導地位。醫療保健專業人員和患者對症狀和風險因素的認知不斷提高，導致這些環境中診斷率的提高。醫院和診所診斷服務的便利性將使外分泌胰臟功能不全的篩檢和檢測變得廣泛，診斷技術的進步將提高 EPI 檢測的準確性和效率，進一步推動該領域的成長。
  • 由於先進的醫療基礎設施、目標疾病盛行率上升以及有利的法規環境等因素，北美在市場上佔據主導地位。

目錄

第1章調查方法和範圍

第 2 章執行摘要

第3章外分泌胰臟功能不全診斷市場的變數、趨勢和範圍

  • 市場體系展望
    • 母市場展望
    • 相關/附隨市場展望
  • 市場動態
    • 市場促進因素分析
    • 市場限制因素分析
  • 胰臟外分泌功能不全診斷市場分析工具
    • 產業分析-波特五力分析
    • PESTEL分析
    • 價格分析
    • 定量分析（實驗室測試設備）

第4章胰臟外分泌功能不全診斷市場：診斷方法估算及趨勢分析

  • 細分儀表板
  • 全球外分泌胰臟功能不全診斷市場波動分析
  • 依診斷方法分：全球外分泌胰臟功能不全診斷市場前景
  • 臨床檢查
  • 影像檢查

第5章胰臟外分泌功能不全診斷市場：最終用途估計與趨勢分析

  • 細分儀表板
  • 全球外分泌胰臟功能不全診斷市場波動分析
  • 全球外分泌胰臟功能不全診斷市場的最終用途與前景
  • 醫院/診所
  • 診斷實驗室
  • 研究機構

第6章胰臟外分泌功能不全診斷市場：依診斷方法和最終用途進行區域估計和趨勢分析

  • 區域儀表板
  • 2018-2030年市場規模、預測趨勢分析：
  • 北美洲
  • 歐洲
  • 亞太地區
  • 拉丁美洲
  • 中東/非洲

第7章 競爭格局

  • 主要市場參與企業的最新趨勢和影響分析
  • 公司/競爭對手分類
  • 供應商情況
    • 主要經銷商及通路夥伴名單
    • 主要客戶
    • 2023年主要企業市場佔有率分析
    • ChiRhoClin
    • Certest Biotec
    • ScheBo Biotech AG
    • Immundiagnostik AG
    • Laboratory Corporation of America Holdings
    • Boster Biological Technology
    • ALPCO Diagnostics
    • Quest Diagnostics Incorporated
    • DiaSorin SpA
    • ARUP Laboratories
    • Verisana Laboratories
    • Alpha Laboratories
Product Code: GVR-4-68040-294-6

Exocrine Pancreatic Insufficiency Diagnostics Market Growth & Trends:

The global exocrine pancreatic insufficiency diagnostics market size is anticipated to reach USD 5.44 billion by 2030 and is growing at a CAGR of 7.2% from 2024 to 2030, according to a new report by Grand View Research, Inc. Exocrine pancreatic insufficiency (EPI) diagnostics are crucial for identifying and managing the condition, especially considering its high prevalence in various patient populations and its association with several underlying causes. One of the major driving factors for diagnostics is the prevalence of patients with chronic pancreatitis. Studies have shown that EPI is prevalent in about 60% to 90% of patients diagnosed with chronic pancreatitis within 10 to 12 years of diagnosis. Chronic pancreatitis is a significant contributor to EPI, and its relatively high prevalence underscores the importance of early detection and management.

Furthermore, advanced pancreatic cancer is another condition strongly associated with the disease. Research indicates that between 66% to 92% of patients with advanced pancreatic cancer develop EPI. Early diagnosis of EPI in these patients can lead to better management of symptoms and improved quality of life. Inflammatory bowel disease (IBD) is also linked to EPI, with studies suggesting that between 14% and 74% of IBD patients may suffer from EPI. Timely diagnosis and treatment of exocrine pancreatic insufficiency in these patients can help alleviate symptoms and improve nutritional status.

In addition, patients undergoing bariatric surgery are at risk of developing EPI despite receiving enzymatic and nutritional supplements. This highlights the importance of ongoing monitoring and diagnostic testing to identify exocrine pancreatic insufficiency in this patient population. Moreover, the prevalence of EPI in patients with HIV/AIDS is estimated to be between 26% and 45%. Early detection of exocrine pancreatic insufficiency in these individuals is essential for optimizing nutritional status and overall health outcomes.

The diverse range of conditions associated with EPI underscores the need for comprehensive diagnostic approaches. Factors driving the demand for exocrine pancreatic insufficiency diagnostics include high prevalence in various patient populations, the association with chronic conditions such as chronic pancreatitis and pancreatic cancer, and the importance of early detection for effective management and improved patient outcomes. As diagnostic technologies advance, early detection and personalized management will become increasingly feasible, leading to better patient care and outcomes.

Key market players such as ChiRhoClin, Inc., Certest Biotec, ScheBo Biotech AG, Immundiagnostik AG, and Laboratory Corporation of America Holdings are at the forefront of innovation in exocrine pancreatic insufficiency diagnostics. These companies are constantly focusing on expanding their products. For instance, in June 2021, CERTEST BIOTEC announced to participate and showcase its product with latest developments at 71st Annual Scientific Meeting and Exhibition of Clinical Laboratories of the AACC held from August 4 to 8 in California.

Exocrine Pancreatic Insufficiency Diagnostics Market Report Highlights:

  • Based on diagnostic method, the laboratory tests segment dominated the overall market with the highest revenue share in 2023. This can be attributed to the extensive advancements such as automation in the laboratory, disposable kits, sample collections & storage, and assays
  • Growing R&D in EPI diagnostics is projected to propel market growth over the forecast period
  • The introduction of new techniques and assays and the integration of established technologies signifies a significant step forward in diagnostics. As awareness about pancreatic disorders continues to grow, fueled by advancements in diagnostic technologies, the U.S. market for stool tests in EPI diagnostics is poised for continued expansion in the coming years
  • The hospitals and clinics end-use segment dominated the market in 2023, driven by several factors. Increased awareness among healthcare professionals and patients about symptoms and risk factors has led to higher diagnosis rates in these settings. Accessibility of diagnostic services in hospitals and clinics facilitates widespread screening and testing for exocrine pancreatic insufficiency, and advancements in diagnostic technologies enhance the accuracy and efficiency of EPI detection, further driving growth in this segment
  • North America dominated the market owing to factors such as advanced healthcare infrastructure, rising prevalence of target diseases, and favorable regulatory environment

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Diagnostic Method
    • 1.2.2. End-use
    • 1.2.3. Regional scope
    • 1.2.4. Estimates and forecasts timeline
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased database
    • 1.4.2. GVR's internal database
    • 1.4.3. Secondary sources
    • 1.4.4. Primary research
    • 1.4.5. Details of primary research
      • 1.4.5.1. Data for primary interviews in North America
      • 1.4.5.2. Data for primary interviews in Europe
      • 1.4.5.3. Data for primary interviews in Asia Pacific
      • 1.4.5.4. Data for primary interviews in Latin America
      • 1.4.5.5. Data for Primary interviews in MEA
  • 1.5. Information or Data Analysis
    • 1.5.1. Data analysis models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Commodity flow analysis (Model 1)
    • 1.7.2. Approach 1: Commodity flow approach
    • 1.7.3. Volume price analysis (Model 2)
    • 1.7.4. Approach 2: Volume price analysis
  • 1.8. List of Secondary Sources
  • 1.9. List of Primary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Diagnostic method Outlook
    • 2.2.2. End-use Outlook
    • 2.2.3. Regional Outlook
  • 2.3. Competitive Insights

Chapter 3. Exocrine Pancreatic Insufficiency Diagnostics Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
      • 3.2.1.1. Increasing disease awareness
      • 3.2.1.2. Focus on early detection
      • 3.2.1.3. Increasing cases of exocrine pancreatic insufficiency
    • 3.2.2. Market Restraint Analysis
      • 3.2.2.1. Regulatory hurdles and compliance requirements
      • 3.2.2.2. Underdiagnosis and misdiagnosis
  • 3.3. Exocrine Pancreatic Insufficiency Diagnostics Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
      • 3.3.1.1. Supplier power
      • 3.3.1.2. Buyer power
      • 3.3.1.3. Substitution threat
      • 3.3.1.4. Threat of new entrant
      • 3.3.1.5. Competitive rivalry
    • 3.3.2. PESTEL Analysis
      • 3.3.2.1. Political landscape
      • 3.3.2.2. Technological landscape
      • 3.3.2.3. Economic landscape
    • 3.3.3. Pricing Analysis
    • 3.3.4. Volume Analysis (Laboratory-based Testing Devices)

Chapter 4. Exocrine Pancreatic Insufficiency Diagnostics Market: Diagnostic Method Estimates & Trend Analysis

  • 4.1. Segment Dashboard
  • 4.2. Global Exocrine Pancreatic Insufficiency Diagnostics Market Movement Analysis
  • 4.3. Global Exocrine Pancreatic Insufficiency Diagnostics Market by Diagnostic Method Outlook
  • 4.4. Laboratory Tests
    • 4.4.1. Laboratory tests market estimates and forecasts 2018 - 2030 (USD Million)
    • 4.4.2. Indirect Pancreatic Function Tests
      • 4.4.2.1. Market estimates and forecasts 2018 - 2030 (USD Million)
      • 4.4.2.2. Stool Tests
      • 4.4.2.2.1. Market estimates and forecasts 2018 - 2030 (USD Million)
      • 4.4.2.3. Blood Tests
      • 4.4.2.3.1. Market estimates and forecasts 2018 - 2030 (USD Million)
    • 4.4.3. Other Tests
      • 4.4.3.1. Market estimates and forecasts 2018 - 2030 (USD Million)
  • 4.5. Imaging Tests
    • 4.5.1. Imaging tests market estimates and forecasts 2018 - 2030 (USD Million)
    • 4.5.2. CT scans
      • 4.5.2.1. Market estimates and forecasts 2018 - 2030 (USD Million)
    • 4.5.3. MRI
      • 4.5.3.1. Market estimates and forecasts 2018 - 2030 (USD Million)
    • 4.5.4. Endoscopic Ultrasound for pancreatic function tests
      • 4.5.4.1. Market estimates and forecasts 2018 - 2030 (USD Million)

Chapter 5. Exocrine Pancreatic Insufficiency Diagnostics Market: End-use Estimates & Trend Analysis

  • 5.1. Segment Dashboard
  • 5.2. Global Exocrine Pancreatic Insufficiency Diagnostics Market Movement Analysis
  • 5.3. Global Exocrine Pancreatic Insufficiency Diagnostics Market by End-use Outlook
  • 5.4. Hospitals & Clinics
    • 5.4.1. Hospitals & Clinics market estimates and forecasts 2018 - 2030 (USD Million)
  • 5.5. Diagnostic Laboratories
    • 5.5.1. Diagnostic laboratories market estimates and forecasts 2018 - 2030 (USD Million)
  • 5.6. Research Institutes
    • 5.6.1. Research Institutes market estimates and forecasts 2018 - 2030 (USD Million)

Chapter 6. Exocrine Pancreatic Insufficiency Diagnostics Market: Regional Estimates & Trend Analysis by Diagnostic Method, and End-use

  • 6.1. Regional Dashboard
  • 6.2. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
  • 6.3. North America
    • 6.3.1. U.S.
      • 6.3.1.1. Key country dynamics
      • 6.3.1.2. Regulatory framework/ reimbursement structure
      • 6.3.1.3. Competitive scenario
      • 6.3.1.4. U.S. market estimates and forecasts 2018 - 2030 (USD Million)
    • 6.3.2. Canada
      • 6.3.2.1. Key country dynamics
      • 6.3.2.2. Regulatory framework/ reimbursement structure
      • 6.3.2.3. Competitive scenario
      • 6.3.2.4. Canada market estimates and forecasts 2018 - 2030 (USD Million)
  • 6.4. Europe
    • 6.4.1. UK
      • 6.4.1.1. Key country dynamics
      • 6.4.1.2. Regulatory framework/ reimbursement structure
      • 6.4.1.3. Competitive scenario
      • 6.4.1.4. UK market estimates and forecasts 2018 - 2030 (USD Million)
    • 6.4.2. Germany
      • 6.4.2.1. Key country dynamics
      • 6.4.2.2. Regulatory framework/ reimbursement structure
      • 6.4.2.3. Competitive scenario
      • 6.4.2.4. Germany market estimates and forecasts 2018 - 2030 (USD Million)
    • 6.4.3. France
      • 6.4.3.1. Key country dynamics
      • 6.4.3.2. Regulatory framework/ reimbursement structure
      • 6.4.3.3. Competitive scenario
      • 6.4.3.4. France market estimates and forecasts 2018 - 2030 (USD Million)
    • 6.4.4. Italy
      • 6.4.4.1. Key country dynamics
      • 6.4.4.2. Regulatory framework/ reimbursement structure
      • 6.4.4.3. Competitive scenario
      • 6.4.4.4. Italy market estimates and forecasts 2018 - 2030 (USD Million)
    • 6.4.5. Spain
      • 6.4.5.1. Key country dynamics
      • 6.4.5.2. Regulatory framework/ reimbursement structure
      • 6.4.5.3. Competitive scenario
      • 6.4.5.4. Spain market estimates and forecasts 2018 - 2030 (USD Million)
    • 6.4.6. Denmark
      • 6.4.6.1. Key country dynamics
      • 6.4.6.2. Regulatory framework/ reimbursement structure
      • 6.4.6.3. Competitive scenario
      • 6.4.6.4. Denmark market estimates and forecasts 2018 - 2030 (USD Million)
    • 6.4.7. Sweden
      • 6.4.7.1. Key country dynamics
      • 6.4.7.2. Regulatory framework/ reimbursement structure
      • 6.4.7.3. Competitive scenario
      • 6.4.7.4. Sweden market estimates and forecasts 2018 - 2030 (USD Million)
    • 6.4.8. Norway
      • 6.4.8.1. Key country dynamics
      • 6.4.8.2. Regulatory framework/ reimbursement structure
      • 6.4.8.3. Competitive scenario
      • 6.4.8.4. Norway market estimates and forecasts 2018 - 2030 (USD Million)
  • 6.5. Asia Pacific
    • 6.5.1. Japan
      • 6.5.1.1. Key country dynamics
      • 6.5.1.2. Regulatory framework/ reimbursement structure
      • 6.5.1.3. Competitive scenario
      • 6.5.1.4. Japan market estimates and forecasts 2018 - 2030 (USD Million)
    • 6.5.2. China
      • 6.5.2.1. Key country dynamics
      • 6.5.2.2. Regulatory framework/ reimbursement structure
      • 6.5.2.3. Competitive scenario
      • 6.5.2.4. China market estimates and forecasts 2018 - 2030 (USD Million)
    • 6.5.3. India
      • 6.5.3.1. Key country dynamics
      • 6.5.3.2. Regulatory framework/ reimbursement structure
      • 6.5.3.3. Competitive scenario
      • 6.5.3.4. India market estimates and forecasts 2018 - 2030 (USD Million)
    • 6.5.4. Australia
      • 6.5.4.1. Key country dynamics
      • 6.5.4.2. Regulatory framework/ reimbursement structure
      • 6.5.4.3. Competitive scenario
      • 6.5.4.4. Australia market estimates and forecasts 2018 - 2030 (USD Million)
    • 6.5.5. Thailand
      • 6.5.5.1. Key country dynamics
      • 6.5.5.2. Regulatory framework/ reimbursement structure
      • 6.5.5.3. Competitive scenario
      • 6.5.5.4. Thailand market estimates and forecasts 2018 - 2030 (USD Million)
    • 6.5.6. South Korea
      • 6.5.6.1. Key country dynamics
      • 6.5.6.2. Regulatory framework/ reimbursement structure
      • 6.5.6.3. Competitive scenario
      • 6.5.6.4. South Korea market estimates and forecasts 2018 - 2030 (USD Million)
  • 6.6. Latin America
    • 6.6.1. Brazil
      • 6.6.1.1. Key country dynamics
      • 6.6.1.2. Regulatory framework/ reimbursement structure
      • 6.6.1.3. Competitive scenario
      • 6.6.1.4. Brazil market estimates and forecasts 2018 - 2030 (USD Million)
    • 6.6.2. Mexico
      • 6.6.2.1. Key country dynamics
      • 6.6.2.2. Regulatory framework/ reimbursement structure
      • 6.6.2.3. Competitive scenario
      • 6.6.2.4. Mexico market estimates and forecasts 2018 - 2030 (USD Million)
    • 6.6.3. Argentina
      • 6.6.3.1. Key country dynamics
      • 6.6.3.2. Regulatory framework/ reimbursement structure
      • 6.6.3.3. Competitive scenario
      • 6.6.3.4. Argentina market estimates and forecasts 2018 - 2030 (USD Million)
  • 6.7. MEA
    • 6.7.1. South Africa
      • 6.7.1.1. Key country dynamics
      • 6.7.1.2. Regulatory framework/ reimbursement structure
      • 6.7.1.3. Competitive scenario
      • 6.7.1.4. South Africa market estimates and forecasts 2018 - 2030 (USD Million)
    • 6.7.2. Saudi Arabia
      • 6.7.2.1. Key country dynamics
      • 6.7.2.2. Regulatory framework/ reimbursement structure
      • 6.7.2.3. Competitive scenario
      • 6.7.2.4. Saudi Arabia market estimates and forecasts 2018 - 2030 (USD Million)
    • 6.7.3. UAE
      • 6.7.3.1. Key country dynamics
      • 6.7.3.2. Regulatory framework/ reimbursement structure
      • 6.7.3.3. Competitive scenario
      • 6.7.3.4. UAE market estimates and forecasts 2018 - 2030 (USD Million)
    • 6.7.4. Kuwait
      • 6.7.4.1. Key country dynamics
      • 6.7.4.2. Regulatory framework/ reimbursement structure
      • 6.7.4.3. Competitive scenario
      • 6.7.4.4. Kuwait market estimates and forecasts 2018 - 2030 (USD Million)

Chapter 7. Competitive Landscape

  • 7.1. Recent Developments & Impact Analysis, By Key Market Participants
  • 7.2. Company/Competition Categorization
  • 7.3. Vendor Landscape
    • 7.3.1. List of key distributors and channel partners
    • 7.3.2. Key customers
    • 7.3.3. Key company market share analysis, 2023
    • 7.3.4. ChiRhoClin
      • 7.3.4.1. Company overview
      • 7.3.4.2. Financial performance
      • 7.3.4.3. Product benchmarking
      • 7.3.4.4. Strategic initiatives
    • 7.3.5. Certest Biotec
      • 7.3.5.1. Company overview
      • 7.3.5.2. Financial performance
      • 7.3.5.3. Product benchmarking
      • 7.3.5.4. Strategic initiatives
    • 7.3.6. ScheBo Biotech AG
      • 7.3.6.1. Company overview
      • 7.3.6.2. Financial performance
      • 7.3.6.3. Product benchmarking
      • 7.3.6.4. Strategic initiatives
    • 7.3.7. Immundiagnostik AG
      • 7.3.7.1. Company overview
      • 7.3.7.2. Financial performance
      • 7.3.7.3. Product benchmarking
      • 7.3.7.4. Strategic initiatives
    • 7.3.8. Laboratory Corporation of America Holdings
      • 7.3.8.1. Company overview
      • 7.3.8.2. Financial performance
      • 7.3.8.3. Product benchmarking
      • 7.3.8.4. Strategic initiatives
    • 7.3.9. Boster Biological Technology
      • 7.3.9.1. Company overview
      • 7.3.9.2. Financial performance
      • 7.3.9.3. Product benchmarking
      • 7.3.9.4. Strategic initiatives
    • 7.3.10. ALPCO Diagnostics
      • 7.3.10.1. Company overview
      • 7.3.10.2. Financial performance
      • 7.3.10.3. Product benchmarking
      • 7.3.10.4. Strategic initiatives
    • 7.3.11. Quest Diagnostics Incorporated
      • 7.3.11.1. Company overview
      • 7.3.11.2. Financial performance
      • 7.3.11.3. Product benchmarking
      • 7.3.11.4. Strategic initiatives
    • 7.3.12. DiaSorin S.p.A.
      • 7.3.12.1. Company overview
      • 7.3.12.2. Financial performance
      • 7.3.12.3. Product benchmarking
      • 7.3.12.4. Strategic initiatives
    • 7.3.13. ARUP Laboratories
      • 7.3.13.1. Company overview
      • 7.3.13.2. Financial performance
      • 7.3.13.3. Product benchmarking
      • 7.3.13.4. Strategic initiatives
    • 7.3.14. Verisana Laboratories
      • 7.3.14.1. Company overview
      • 7.3.14.2. Financial performance
      • 7.3.14.3. Product benchmarking
      • 7.3.14.4. Strategic initiatives
    • 7.3.15. Alpha Laboratories
      • 7.3.15.1. Company overview
      • 7.3.15.2. Financial performance
      • 7.3.15.3. Product benchmarking
      • 7.3.15.4. Strategic initiatives

List of Tables

  • Table 1 List of abbreviation
  • Table 2 North America exocrine pancreatic insufficiency diagnostics market, by region, 2018 - 2030 (USD Million)
  • Table 3 North America exocrine pancreatic insufficiency diagnostics market, by diagnostic method, 2018 - 2030 (USD Million)
  • Table 4 North America exocrine pancreatic insufficiency diagnostics market, by end-use, 2018 - 2030 (USD Million)
  • Table 5 U.S. exocrine pancreatic insufficiency diagnostics market, by diagnostic method, 2018 - 2030 (USD Million)
  • Table 6 U.S. exocrine pancreatic insufficiency diagnostics market, by end-use, 2018 - 2030 (USD Million)
  • Table 7 Canada exocrine pancreatic insufficiency diagnostics market, by diagnostic method, 2018 - 2030 (USD Million)
  • Table 8 Canada exocrine pancreatic insufficiency diagnostics market, by end-use, 2018 - 2030 (USD Million)
  • Table 9 Europe exocrine pancreatic insufficiency diagnostics market, by region, 2018 - 2030 (USD Million)
  • Table 10 Europe exocrine pancreatic insufficiency diagnostics market, by diagnostic method, 2018 - 2030 (USD Million)
  • Table 11 Europe exocrine pancreatic insufficiency diagnostics market, by end-use, 2018 - 2030 (USD Million)
  • Table 12 Germany exocrine pancreatic insufficiency diagnostics market, by diagnostic method, 2018 - 2030 (USD Million)
  • Table 13 Germany exocrine pancreatic insufficiency diagnostics market, by end-use, 2018 - 2030 (USD Million)
  • Table 14 UK exocrine pancreatic insufficiency diagnostics market, by diagnostic method, 2018 - 2030 (USD Million)
  • Table 15 UK exocrine pancreatic insufficiency diagnostics market, by end-use, 2018 - 2030 (USD Million)
  • Table 16 France exocrine pancreatic insufficiency diagnostics market, by diagnostic method, 2018 - 2030 (USD Million)
  • Table 17 France exocrine pancreatic insufficiency diagnostics market, by end-use, 2018 - 2030 (USD Million)
  • Table 18 Italy exocrine pancreatic insufficiency diagnostics market, by diagnostic method, 2018 - 2030 (USD Million)
  • Table 19 Italy exocrine pancreatic insufficiency diagnostics market, by end-use, 2018 - 2030 (USD Million)
  • Table 20 Spain exocrine pancreatic insufficiency diagnostics market, by diagnostic method, 2018 - 2030 (USD Million)
  • Table 21 Spain exocrine pancreatic insufficiency diagnostics market, by end-use, 2018 - 2030 (USD Million)
  • Table 22 Denmark exocrine pancreatic insufficiency diagnostics market, by diagnostic method, 2018 - 2030 (USD Million)
  • Table 23 Denmark exocrine pancreatic insufficiency diagnostics market, by end-use, 2018 - 2030 (USD Million)
  • Table 24 Sweden exocrine pancreatic insufficiency diagnostics market, by diagnostic method, 2018 - 2030 (USD Million)
  • Table 25 Sweden exocrine pancreatic insufficiency diagnostics market, by end-use, 2018 - 2030 (USD Million)
  • Table 26 Norway exocrine pancreatic insufficiency diagnostics market, by diagnostic method, 2018 - 2030 (USD Million)
  • Table 27 Norway exocrine pancreatic insufficiency diagnostics market, by end-use, 2018 - 2030 (USD Million)
  • Table 28 Asia Pacific exocrine pancreatic insufficiency diagnostics market, by region 2018 - 2030 (USD Million)
  • Table 29 Asia Pacific exocrine pancreatic insufficiency diagnostics market, by diagnostic method, 2018 - 2030 (USD Million)
  • Table 30 Aisa Pacific exocrine pancreatic insufficiency diagnostics market, by end-use, 2018 - 2030 (USD Million)
  • Table 31 Japan exocrine pancreatic insufficiency diagnostics market, by diagnostic method, 2018 - 2030 (USD Million)
  • Table 32 Japan exocrine pancreatic insufficiency diagnostics market, by end-use, 2018 - 2030 (USD Million)
  • Table 33 China exocrine pancreatic insufficiency diagnostics market, by diagnostic method, 2018 - 2030 (USD Million)
  • Table 34 China exocrine pancreatic insufficiency diagnostics market, by end-use, 2018 - 2030 (USD Million)
  • Table 35 India exocrine pancreatic insufficiency diagnostics market, by diagnostic method, 2018 - 2030 (USD Million)
  • Table 36 India exocrine pancreatic insufficiency diagnostics market, by end-use, 2018 - 2030 (USD Million)
  • Table 37 Australia exocrine pancreatic insufficiency diagnostics market, by diagnostic method, 2018 - 2030 (USD Million)
  • Table 38 Australia exocrine pancreatic insufficiency diagnostics market, by end-use, 2018 - 2030 (USD Million)
  • Table 39 Thailand exocrine pancreatic insufficiency diagnostics market, by diagnostic method, 2018 - 2030 (USD Million)
  • Table 40 Thailand exocrine pancreatic insufficiency diagnostics market, by end-use, 2018 - 2030 (USD Million)
  • Table 41 South Korea exocrine pancreatic insufficiency diagnostics market, by diagnostic method, 2018 - 2030 (USD Million)
  • Table 42 South Korea exocrine pancreatic insufficiency diagnostics market, by end-use, 2018 - 2030 (USD Million)
  • Table 43 Latin America exocrine pancreatic insufficiency diagnostics market, by region, 2018 - 2030 (USD Million)
  • Table 44 Latin America exocrine pancreatic insufficiency diagnostics market, by diagnostic method, 2018 - 2030 (USD Million)
  • Table 45 Latin America exocrine pancreatic insufficiency diagnostics market, by end-use, 2018 - 2030 (USD Million)
  • Table 46 Brazil exocrine pancreatic insufficiency diagnostics market, by diagnostic method, 2018 - 2030 (USD Million)
  • Table 47 Brazil exocrine pancreatic insufficiency diagnostics market, by end-use, 2018 - 2030 (USD Million)
  • Table 48 Mexico exocrine pancreatic insufficiency diagnostics market, by diagnostic method, 2018 - 2030 (USD Million)
  • Table 49 Mexico exocrine pancreatic insufficiency diagnostics market, by end-use, 2018 - 2030 (USD Million)
  • Table 50 Argentina exocrine pancreatic insufficiency diagnostics market, by diagnostic method, 2018 - 2030 (USD Million)
  • Table 51 Argentina exocrine pancreatic insufficiency diagnostics market, by end-use, 2018 - 2030 (USD Million)
  • Table 52 MEA exocrine pancreatic insufficiency diagnostics market, by region, 2018 - 2030 (USD Million)
  • Table 53 MEA exocrine pancreatic insufficiency diagnostics market, by diagnostic method, 2018 - 2030 (USD Million)
  • Table 54 MEA exocrine pancreatic insufficiency diagnostics market, by end-use, 2018 - 2030 (USD Million)
  • Table 55 South Africa exocrine pancreatic insufficiency diagnostics market, by diagnostic method, 2018 - 2030 (USD Million)
  • Table 56 South Africa exocrine pancreatic insufficiency diagnostics market, by end-use, 2018 - 2030 (USD Million)
  • Table 57 Saudi Arabia exocrine pancreatic insufficiency diagnostics market, by diagnostic method, 2018 - 2030 (USD Million)
  • Table 58 Saudi Arabia exocrine pancreatic insufficiency diagnostics market, by end-use, 2018 - 2030 (USD Million)
  • Table 59 UAE exocrine pancreatic insufficiency diagnostics market, by diagnostic method, 2018 - 2030 (USD Million)
  • Table 60 UAE exocrine pancreatic insufficiency diagnostics market, by end-use, 2018 - 2030 (USD Million)
  • Table 61 Kuwait exocrine pancreatic insufficiency diagnostics market, by diagnostic method, 2018 - 2030 (USD Million)
  • Table 62 Kuwait exocrine pancreatic insufficiency diagnostics market, by end-use, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Data triangulation techniques
  • Fig. 3 Primary research pattern
  • Fig. 4 Primary interviews in North America
  • Fig. 5 Primary interviews in Europe
  • Fig. 6 Primary interviews in Asia Pacific
  • Fig. 7 Primary interviews in Latin America
  • Fig. 8 Primary interviews in MEA
  • Fig. 9 Market research approaches
  • Fig. 10 Value-chain-based sizing & forecasting
  • Fig. 11 QFD modeling for market share assessment
  • Fig. 12 Market formulation & validation
  • Fig. 13 Exocrine pancreatic insufficiency diagnostics market: market outlook
  • Fig. 14 Parent market outlook
  • Fig. 15 Related/ancillary market outlook
  • Fig. 16 Exocrine pancreatic insufficiency diagnostics market driver impact
  • Fig. 17 Exocrine pancreatic insufficiency diagnostics market restraint impact
  • Fig. 18 Exocrine pancreatic insufficiency diagnostics market: Diagnostic method movement analysis
  • Fig. 19 Exocrine pancreatic insufficiency diagnostics market: Diagnostic method outlook and key takeaways
  • Fig. 20 Laboratory tests market estimates and forecast, 2018 - 2030
  • Fig. 21 Indirect pancreatic function tests market estimates and forecast, 2018 - 2030
  • Fig. 22 Stool tests market estimates and forecast, 2018 - 2030
  • Fig. 23 Blood tests market estimates and forecast, 2018 - 2030
  • Fig. 24 Other tests market estimates and forecast, 2018 - 2030
  • Fig. 25 Imaging tests market estimates and forecast, 2018 - 2030
  • Fig. 26 CT scans market estimates and forecast, 2018 - 2030
  • Fig. 27 MRI market estimates and forecast, 2018 - 2030
  • Fig. 28 Endoscopic ultrasound for pancreatic function tests market estimates and forecast, 2018 2030
  • Fig. 29 Exocrine pancreatic insufficiency diagnostics market: End-use movement analysis
  • Fig. 30 Exocrine pancreatic insufficiency diagnostics market: End-use outlook and key takeaways
  • Fig. 31 Hospitals & clinics market estimates and forecast, 2018 - 2030
  • Fig. 32 Diagnostic laboratories estimates and forecast, 2018 - 2030
  • Fig. 33 Research institutes market estimates and forecast, 2018 - 2030
  • Fig. 34 Global Exocrine pancreatic insufficiency diagnostics market: Regional movement analysis
  • Fig. 35 Global Exocrine pancreatic insufficiency diagnostics market: Regional outlook and key takeaways
  • Fig. 36 Global Exocrine pancreatic insufficiency diagnostics market share and leading players
  • Fig. 37 North America
  • Fig. 38 North America market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 39 U.S. key country dynamics
  • Fig. 40 U.S. market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 41 Canada key country dynamics
  • Fig. 42 Canada market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 43 Europe
  • Fig. 44 Europe market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 45 UK key country dynamics
  • Fig. 46 UK market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 47 Germany key country dynamics
  • Fig. 48 Germany market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 49 France key country dynamics
  • Fig. 50 France market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 51 Italy key country dynamics
  • Fig. 52 Italy market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 53 Spain key country dynamics
  • Fig. 54 Spain market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 55 Denmark key country dynamics
  • Fig. 56 Denmark market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 57 Sweden key country dynamics
  • Fig. 58 Sweden market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 59 Norway key country dynamics
  • Fig. 60 Norway market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 61 Asia Pacific
  • Fig. 62 Asia Pacific market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 63 China key country dynamics
  • Fig. 64 China market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 65 Japan key country dynamics
  • Fig. 66 Japan market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 67 India key country dynamics
  • Fig. 68 India market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 69 Australia key country dynamics
  • Fig. 70 Australia market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 71 Thailand key country dynamics
  • Fig. 72 Thailand market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 73 South Korea key country dynamics
  • Fig. 74 South Korea market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 75 Latin America
  • Fig. 76 Latin America market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 77 Brazil key country dynamics
  • Fig. 78 Brazil market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 79 Mexico key country dynamics
  • Fig. 80 Mexico market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 81 Argentina key country dynamics
  • Fig. 82 Argentina market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 83 Middle East and Africa
  • Fig. 84 Middle East and Africa market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 85 South Africa key country dynamics
  • Fig. 86 South Africa market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 87 Saudi Arabia key country dynamics
  • Fig. 88 Saudi Arabia market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 89 UAE key country dynamics
  • Fig. 90 UAE market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 91 Kuwait key country dynamics
  • Fig. 92 Kuwait market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 93 Market share of key market players- Exocrine pancreatic insufficiency diagnostics market